Burton Matthew J, Rajak Saul N, Hu Victor H, Ramadhani Athumani, Habtamu Esmael, Massae Patrick, Tadesse Zerihun, Callahan Kelly, Emerson Paul M, Khaw Peng T, Jeffries David, Mabey David C W, Bailey Robin L, Weiss Helen A, Holland Martin J
Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London (UCL) Institute of Ophthalmology, London, United Kingdom; Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
PLoS Negl Trop Dis. 2015 May 13;9(5):e0003763. doi: 10.1371/journal.pntd.0003763. eCollection 2015 May.
Trachoma causes blindness through a conjunctival scarring process initiated by ocular Chlamydia trachomatis infection; however, the rates, drivers and pathophysiological determinants are poorly understood. We investigated progressive scarring and its relationship to conjunctival infection, inflammation and transcript levels of cytokines and fibrogenic factors.
METHODOLOGY/PRINCIPAL FINDINGS: We recruited two cohorts, one each in Ethiopia and Tanzania, of individuals with established trachomatous conjunctival scarring. They were followed six-monthly for two years, with clinical examinations and conjunctival swab sample collection. Progressive scarring cases were identified by comparing baseline and two-year photographs, and compared to individuals without progression. Samples were tested for C. trachomatis by PCR and transcript levels of S100A7, IL1B, IL13, IL17A, CXCL5, CTGF, SPARCL1, CEACAM5, MMP7, MMP9 and CD83 were estimated by quantitative RT-PCR. Progressive scarring was found in 135/585 (23.1%) of Ethiopian participants and 173/577 (30.0%) of Tanzanian participants. There was a strong relationship between progressive scarring and increasing inflammatory episodes (Ethiopia: OR 5.93, 95%CI 3.31-10.6, p<0.0001. Tanzania: OR 5.76, 95%CI 2.60-12.7, p<0.0001). No episodes of C. trachomatis infection were detected in the Ethiopian cohort and only 5 episodes in the Tanzanian cohort. Clinical inflammation, but not scarring progression, was associated with increased expression of S100A7, IL1B, IL17A, CXCL5, CTGF, CEACAM5, MMP7, CD83 and reduced SPARCL1.
CONCLUSIONS/SIGNIFICANCE: Scarring progressed in the absence of detectable C. trachomatis, which raises uncertainty about the primary drivers of late-stage trachoma. Chronic conjunctival inflammation appears to be central and is associated with enriched expression of pro-inflammatory factors and altered expression of extracellular matrix regulators. Host determinants of scarring progression appear more complex and subtle than the features of inflammation. Overall this indicates a potential role for anti-inflammatory interventions to interrupt progression and the need for trichiasis disease surveillance and surgery long after chlamydial infection has been controlled at community level.
沙眼通过沙眼衣原体眼部感染引发的结膜瘢痕形成过程导致失明;然而,其发生率、驱动因素和病理生理决定因素尚不清楚。我们研究了渐进性瘢痕形成及其与结膜感染、炎症以及细胞因子和纤维化因子转录水平的关系。
方法/主要发现:我们招募了两个队列,分别来自埃塞俄比亚和坦桑尼亚,均为患有沙眼性结膜瘢痕的个体。对他们每六个月进行一次为期两年的随访,包括临床检查和结膜拭子样本采集。通过比较基线照片和两年后的照片确定渐进性瘢痕形成病例,并与无进展的个体进行比较。通过聚合酶链反应(PCR)检测沙眼衣原体,通过定量逆转录聚合酶链反应(qRT-PCR)估计S100A7、IL1B、IL13、IL17A、CXCL5、CTGF、SPARCL1、CEACAM5、MMP7、MMP9和CD83的转录水平。在埃塞俄比亚参与者中,135/585(23.1%)出现渐进性瘢痕形成;在坦桑尼亚参与者中,173/577(30.0%)出现渐进性瘢痕形成。渐进性瘢痕形成与炎症发作增加之间存在密切关系(埃塞俄比亚:比值比5.93,95%置信区间3.31 - 10.6,p<0.0001。坦桑尼亚:比值比5.76,95%置信区间2.60 - 12.7,p<0.0001)。在埃塞俄比亚队列中未检测到沙眼衣原体感染病例,在坦桑尼亚队列中仅检测到5例。临床炎症与S100A7、IL1B、IL17A、CXCL5、CTGF、CEACAM5、MMP7、CD83表达增加以及SPARCL1表达降低相关,但与瘢痕进展无关。
结论/意义:在未检测到沙眼衣原体的情况下瘢痕仍有进展,这增加了对晚期沙眼主要驱动因素的不确定性。慢性结膜炎症似乎是核心因素,并且与促炎因子表达增加和细胞外基质调节因子表达改变有关。瘢痕进展的宿主决定因素似乎比炎症特征更为复杂和微妙。总体而言,这表明抗炎干预在中断进展方面具有潜在作用,并且在社区层面衣原体感染得到控制后很长时间仍需要进行倒睫疾病监测和手术。